In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?

Currently, the FDA's only indication for Besremi (ropeginterferon) is polycythemia vera (PV). I am not sure why this is since there is ample data on treating essential thrombocytosis (ET) patients with pegylated interferon. So, if still available, my answer covers the use of either. It also covers E...

In patients who progress on hydroxyurea and anagrelide or refractory to them.